<DOC>
	<DOCNO>NCT00179062</DOCNO>
	<brief_summary>This twelve month , open-label study considers effect Risperdal ( risperidone ) versus Zyprexa ( olanzapine ) weight gain , physical health , outcome population diagnose schizophrenia , schizoaffective disorder , major depression bipolar disorder psychotic feature . This study evaluate symptom response well general health indicator body mass index , glucose , prolactin , cholesterol level baseline , month ( M ) 1 , M3 , M6 M12 .</brief_summary>
	<brief_title>Effects Risperidone Olanzapine Patients With Schizophrenia , Schizoaffective Disorder , Major Depression Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subjects must meet follow criterion eligible participation current research study . 1 . Subjects males female 1860 year age 2 . Subjects definite diagnosis DSMIV criterion schizophrenia , schizoaffective disorder , bipolar disorder major depression psychotic symptom . 3 . Subjects may outpatients inpatient time entry . They continue study hospitalization occur . 4 . The subject legal guardian must sign informed consent form . Subjects meet follow criterion exclude consideration current research project . 1 . Subjects exclude Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) diagnosis schizophrenia , schizoaffective disorder , bipolar disorder depression psychotic feature ; however , concurrent diagnosis posttraumatic stress disorder , account subject 's psychosis acceptable.. 2 . Subject receive continuous treatment olanzapine risperidone last two month . 3 . Subjects receive continuous treatment olanzapine risperidone last two month prior enter study exclude . This mean subject actually take olanzapine risperidone daily four week prior enrollment . There must gap least two day take medication period . The dose olanzapine exceed 10 mg /day , dose risperidone 2 mg/day . The last day exposure kind least seven day baseline . 4 . Subject diagnose treatment refractory . 5 . Subjects unable speak read English language . 6 . Subjects DSMIV diagnosis substance dependence within three month prior selection . Occasional abuse ( define binge per week ) preclude entry . 7 . Subjects document disease central nervous system , include limited stroke , tumor , Parkinson 's disease , Alzheimer 's disease , Huntington 's disease , seizure disorder require anticonvulsant , history brain trauma result documented impairment , chronic infection , neurosyphilis . 8 . Subjects hepatic , renal , atherosclerotic heart disease , arrhythmias gastrointestinal disease sufficient degree interfere excretion , absorption , and/or metabolism trial medication . 9 . Subjects clinical sign liver disease exclude . 10 . Subjects acute ( e.g . infection ) , unstable ( e.g . labile hypertension , unstable angina ) , significant , untreated medical illness ; patient diastolic blood pressure &gt; 95 mmHg screening treat stabilized randomization . 11 . Subjects narrow angle glaucoma , chronic urinary retention and/or clinically significant prostatic hypertrophy , paralytic ileus related condition , opinion investigator may exacerbate anticholinergic effect olanzapine . 12 . Subjects know eat disorder 13 . Female subject pregnant breastfeed 14 . Subjects treat depot neuroleptic within one treatment cycle begin washout period . 15 . Subjects history neuroleptic malignant syndrome . 16 . Subjects highrisk suicide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>major depression psychotic feature</keyword>
	<keyword>bipolar disorder psychotic feature</keyword>
</DOC>